Recommendations for the Equitable and Widespread Implementation of Liquid Biopsy for Cancer Care.
Phillip G FebboMina AlloEmma B AlmeGebra Cuyun CarterRobert DumanoisAlessia EssigEstevan KiernanCaitlin B KublerNikki A MartinMedeea C PopescuLauren C LeimanPublished in: JCO precision oncology (2024)
Liquid biopsies-tests that detect circulating tumor cellular components in the bloodstream-have the potential to transform cancer by reducing health inequities in screening, diagnostics, and monitoring. Today, liquid biopsies are being used to guide treatment choices for patients and monitor for cancer recurrence, and promising work in multi-cancer early detection is ongoing. However, without awareness of the barriers to adoption of this new technology and a willingness to build mitigation efforts into the implementation of widespread liquid biopsy testing, the communities that could most benefit may be the last to access and use them. In this work, we review the challenges likely to affect the accessibility of liquid biopsies in both the general population and underserved populations, and recommend specific actions to facilitate equitable access for all patients.
Keyphrases
- papillary thyroid
- end stage renal disease
- healthcare
- ionic liquid
- newly diagnosed
- ejection fraction
- ultrasound guided
- primary care
- public health
- quality improvement
- squamous cell
- peritoneal dialysis
- mental health
- climate change
- squamous cell carcinoma
- circulating tumor
- patient reported outcomes
- lymph node metastasis
- health information
- human health
- replacement therapy
- combination therapy